Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK. Kamat AA, et al. Among authors: coleman rl. Cancer. 2010 Apr 15;116(8):1918-25. doi: 10.1002/cncr.24997. Cancer. 2010. PMID: 20166213 Free PMC article.
Therapeutic advances in women's cancers.
Carroll AR, Coleman RL, Sood AK. Carroll AR, et al. Among authors: coleman rl. Front Biosci (Schol Ed). 2011 Jan 1;3(1):82-97. doi: 10.2741/s134. Front Biosci (Schol Ed). 2011. PMID: 21196359 Free PMC article. Review.
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr. Fu S, et al. Among authors: coleman rl. Cancer. 2011 Apr 15;117(8):1661-9. doi: 10.1002/cncr.25701. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472713 Free PMC article. Clinical Trial.
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. Meyer LA, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2014 May;24(4):713-7. doi: 10.1097/IGC.0000000000000118. Int J Gynecol Cancer. 2014. PMID: 24651628 Free PMC article. Clinical Trial.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
Management and Treatment of Recurrent Epithelial Ovarian Cancer.
Armbruster S, Coleman RL, Rauh-Hain JA. Armbruster S, et al. Among authors: coleman rl. Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005. Hematol Oncol Clin North Am. 2018. PMID: 30390768 Review.
Exploring and comparing adverse events between PARP inhibitors.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. LaFargue CJ, et al. Among authors: coleman rl. Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1. Lancet Oncol. 2019. PMID: 30614472 Free PMC article. Review.
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Bast RC Jr, et al. Among authors: coleman rl. Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5. Cancer. 2019. PMID: 30835824 Free PMC article.
Joint ENGOT and GOG Foundation requirements for trials with industry partners.
Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez Martin A, Copeland LJ; European Network of Gynaecological Oncological Trial Groups (ENGOT) and The GOG Foundation, Inc. Vergote I, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2019 Sep;29(7):1094-1097. doi: 10.1136/ijgc-2019-000441. Epub 2019 Jul 18. Int J Gynecol Cancer. 2019. PMID: 31320391 No abstract available.
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Myers AP, et al. Among authors: coleman rl. Int J Cancer. 2020 Jul 15;147(2):413-422. doi: 10.1002/ijc.32783. Epub 2019 Dec 13. Int J Cancer. 2020. PMID: 31714586 Free PMC article. Clinical Trial.
European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.
Rees M, Angioli R, Coleman RL, Glasspool RM, Plotti F, Simoncini T, Terranova C. Rees M, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2020 Apr;30(4):428-433. doi: 10.1136/ijgc-2020-001217. Epub 2020 Feb 11. Int J Gynecol Cancer. 2020. PMID: 32046979
Innovation abounds in cancer therapy.
Coleman RL. Coleman RL. Int J Gynecol Cancer. 2020 Apr;30(4):424-425. doi: 10.1136/ijgc-2020-001337. Epub 2020 Mar 18. Int J Gynecol Cancer. 2020. PMID: 32193218 No abstract available.
Improving response to progestin treatment of low-grade endometrial cancer.
Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, Amant F, van Gent MDJM, Huntsman DG, Coleman RL, Westin SN, Yates MS, Krakstad C, Quinn MA, Janda M, Obermair A. Baxter E, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2020 Nov;30(11):1811-1823. doi: 10.1136/ijgc-2020-001309. Epub 2020 May 6. Int J Gynecol Cancer. 2020. PMID: 32381512 Free PMC article. Review.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S. Mirza MR, et al. Among authors: coleman rl. Ann Oncol. 2020 Sep;31(9):1148-1159. doi: 10.1016/j.annonc.2020.06.004. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32569725 Free article. Review.
Two viral infections in Japan.
Fujiwara K, Quinn MA, Coleman RL, Angioli R. Fujiwara K, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2020 Aug;30(8):1258-1259. doi: 10.1136/ijgc-2020-001735. Epub 2020 Jul 16. Int J Gynecol Cancer. 2020. PMID: 32675255 Free PMC article. No abstract available.
Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).
Nitecki R, Rauh-Hain JA, Melamed A, Scambia G, Pareja R, Coleman RL, Ramirez PT, Fagotti A. Nitecki R, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2020 Sep;30(9):1450-1454. doi: 10.1136/ijgc-2020-001584. Epub 2020 Jul 20. Int J Gynecol Cancer. 2020. PMID: 32690591 Free PMC article.
Breast cancer (BRCA) gene testing in ovarian cancer.
Chelariu-Raicu A, Coleman RL. Chelariu-Raicu A, et al. Among authors: coleman rl. Chin Clin Oncol. 2020 Oct;9(5):63. doi: 10.21037/cco-20-4. Epub 2020 Aug 19. Chin Clin Oncol. 2020. PMID: 32819112 Free article. Review.
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.
Kim MS, Ma S, Chelariu-Raicu A, Leuschner C, Alila HW, Lee S, Coleman RL, Sood AK. Kim MS, et al. Among authors: coleman rl. Mol Cancer Ther. 2020 Nov;19(11):2396-2406. doi: 10.1158/1535-7163.MCT-20-0030. Epub 2020 Sep 17. Mol Cancer Ther. 2020. PMID: 32943548 Free PMC article.
PARP inhibition as frontline therapy in ovarian cancer.
Moore KN, Pothuri B, Monk B, Coleman RL. Moore KN, et al. Among authors: coleman rl. Clin Adv Hematol Oncol. 2020 Sep;18(9):550-556. Clin Adv Hematol Oncol. 2020. PMID: 33006584 Review.
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer.
Chelariu-Raicu A, Levenback CF, Slomovitz BM, Wolf J, Bodurka DC, Kavanagh JJ, Morrison C, Gershenson DM, Coleman RL. Chelariu-Raicu A, et al. Among authors: coleman rl. Int J Gynecol Cancer. 2020 Nov;30(11):1768-1774. doi: 10.1136/ijgc-2020-001863. Epub 2020 Oct 9. Int J Gynecol Cancer. 2020. PMID: 33037105 Clinical Trial.
589 results